# Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

> **NCT02750800** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 427 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Psoriasis
- Crohn's Disease
- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** Adalimumab
- **BEHAVIORAL:** AbbVie Care 2.0

## Key facts

- **NCT ID:** NCT02750800
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-07
- **Primary completion:** 2018-04-03
- **Final completion:** 2018-04-03
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02750800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02750800, "Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02750800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*